Evaluation of drug concentration according to genotype and inflammation by cardiopulmonary bypass surgery

Not Applicable

Completed

• Conditions: Diseases of the circulatory system

• Registration Number: KCT0008742
• Lead Sponsor: Gachon University Gil Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2022-06-30
• Last Update Posted: 18 September 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1)Patient who received open heart surgery in Department of Thoracic and Cardiovascular Surgery, Gachon University Gil Medical Center
2)Adult aged 19 years or above
3)Patient who received heart surgery using cardiopulmonary bypass
4)Voluntarily signed and dated written informed consent after sufficient explanation about the full nature and purpose of the study
5) Patient has the ability and will to participate during study period.

Exclusion Criteria

1)Patient who received renal replacement therapy
2)Patient who was on special diets or drugs that were known to modulate drug metabolizing enzymes or affect absorption, distribution, metabolism and excretion of drug
3)Patients judged not eligible for the study after reviewing the clinical laboratory results or other reasons by the investigator

Study & Design

• Study Type: Observational Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clearance of sufentanil

Secondary Outcome Measures

Name	Time	Method
Concentration of sufentanil at steady state